1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Enrollment closed, study ongoing
Also in this update: Enrollment reduced: 77 → 60 participants; Primary completion date changed from estimate of Dec 1, 2026 to Jul 31, 2026
The First Affiliated Hospital of Soochow UniversityPhase 2 NCT06379360 Registry history of NCT06379360 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-02 | NCT07854652 BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute… | Phase 1 | Recruiting |
| Early Phase 1 | 4 | |
| Phase 1 | 10 | |
| Phase 1/2 | 8 | |
| Phase 2 | 40 | |
| Phase 2/3 | 8 | |
| Phase 3 | 7 | |
| Phase 4 | 4 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07270835 | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma | Hemophagocytic Lymphohistiocytosis | Recruiting | 2025-12-08 |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease… | Newly Diagnosed | Recruiting | 2025-06-12 |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly… | Newly Diagnosed Multiple Myeloma | Not Yet Recruiting | 2026-07-17 |
| NCT06504030 | Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis | Hemophagocytic Lymphohistiocytoses | Not Yet Recruiting | 2024-08-05 |
| Phase 3 | ||||
| NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | Acute Myeloid Leukemia (AML) | Recruiting | 2026-03-20 |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | Acute T Cell Lymphoblastic Leukemia | Recruiting | 2024-04-26 |
| NCT07635511 | Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies | Hematological Malignancies | Not Yet Recruiting | 2026-06-09 |
| NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and… | Acute Myeloid Leukemia (AML) | Not Yet Recruiting | 2026-03-20 |
| NCT06673459 | BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients | T-Cell Lymphocytic Leukemia | Not Yet Recruiting | 2024-11-05 |
| NCT05907499 | Decitabine for Poor Graft Function Post Allo-HSCT | Poor Graft Function | Not Yet Recruiting | 2023-06-18 |
| NCT05669079 | Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT | Poor Graft Function | Not Yet Recruiting | 2023-06-09 |
| Phase 2/3 | ||||
| NCT05939180 | VA vs DA for Newly Diagnosed Hig-risk AML | Acute Myeloid Leukemia | Recruiting | 2026-09-02 |
| NCT07583888 | VABu Conditioning in Elderly AML HSCT | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Recruiting | 2026-05-14 |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | Acute Myeloid Leukemia | Recruiting | 2023-04-07 |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | Acute Myeloid Leukemia (AML) in Remission | Recruiting | 2022-08-19 |
| NCT07279610 | N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy | Thrombotic Microangiopathy | Active, Not Recruiting | 2025-12-12 |
| NCT06951971 | Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic… | Hemophagocytic Lymphohistiocytosis (HLH) | Not Yet Recruiting | 2025-04-30 |
| NCT06544109 | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia… | Acute Promyelocytic Leukemia | Enrolling by Invitation | 2024-08-09 |
| NCT05568147 | Aspirin for Prophylaxis of TTP | Thrombotic Thrombocytopenic Purpura | Not Yet Recruiting | 2022-10-05 |
| Phase 2 | ||||
| NCT06486337 | CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma | NHL | Recruiting | 2026-09-09 |
| NCT07425782 | Venetoclax Combined With Azacitidine for Consolidation Therapy in AML | Acute Myeloid Leukemia | Recruiting | 2026-08-06 |
| NCT07672262 | VA Consolidation in Intermediate-Risk AML | Acute Myeloid Leukemia | Recruiting | 2026-08-06 |
| NCT07647263 | Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast… | HER2-positive Breast Cancer | Recruiting | 2026-06-15 |
| NCT07564453 | Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute… | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Recruiting | 2026-05-04 |
| NCT05182957 | Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory… | Relapsed/Refractory Peripheral T-cell Lymphoma | Recruiting | 2026-05-01 |
Leukemia (55) · Acute Myeloid Leukemia (AML) (31) · Acute Lymphoblastic Leukemia (ALL) (20) · Non-Hodgkin Lymphoma (15) · Multiple Myeloma (11) · DLBCL (7) · Myelodysplastic Syndromes (MDS) (5) · Asthma (1) · Atopic Dermatitis (1) · Breast Cancer (1)